Display options
Cite
Hägerström E, Lindberg L, Bentzen J, et al. The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clin Med Insights Oncol. 2019;13:1179554918821320doi: 10.1177/1179554918821320.
Hägerström, E., Lindberg, L., Bentzen, J., Brødbæk, K., Zerahn, B., & Kristensen, B. (2019). The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clinical Medicine Insights. Oncology, 131179554918821320. https://doi.org/10.1177/1179554918821320
Hägerström, Erik, et al. "The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy." Clinical Medicine Insights. Oncology vol. 13 (2019): 1179554918821320. doi: https://doi.org/10.1177/1179554918821320
Hägerström E, Lindberg L, Bentzen J, Brødbæk K, Zerahn B, Kristensen B. The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy. Clin Med Insights Oncol. 2019 Jan 07;13:1179554918821320. doi: 10.1177/1179554918821320. eCollection 2019. PMID: 30670924; PMCID: PMC6327333.
Copy Download .nbib Format: NLM
Share it on

Clin Med Insights Oncol. 2019 Jan 07;13:1179554918821320. doi: 10.1177/1179554918821320. eCollection 2019.

The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy.

Clinical Medicine Insights. Oncology

Erik Hägerström, Lotte Lindberg, Jens Bentzen, Kasper Brødbæk, Bo Zerahn, Bent Kristensen

Affiliations

  1. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
  2. Department of Clinical Physiology and Nuclear Medicine, Herlev Hospital, Herlev, Denmark.
  3. Department of Oncology, Herlev Hospital, Herlev, Denmark.
  4. Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

PMID: 30670924 PMCID: PMC6327333 DOI: 10.1177/1179554918821320

Abstract

INTRODUCTION: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results.

OBJECTIVE: To investigate changes in kidney function in head and neck cancer patients treated with cisplatin with and without additional mannitol infusion.

METHODS: A single center, retrospective cohort study of patients with squamous cell carcinoma of the head and neck receiving radiotherapy with cisplatin. Patient data were collected from November 2013 to December 2014.

RESULTS: After exclusion, a total of 78 patients were considered evaluable. They were equally distributed between a mannitol and a non-mannitol group and anthropomorphometrically similar.

CONCLUSIONS: There was a significantly smaller decrease in

Keywords: Chemotherapy; head and neck cancer; hypopharyngeal cancer; laryngeal cancer; oropharyngeal cancer; radiotherapy; squamous cell carcinoma of the head and neck; toxicity management

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Cancer Chemother Pharmacol. 2003 Jul;52(1):13-8 - PubMed
  2. J Oncol Pharm Pract. 2010 Sep;16(3):167-71 - PubMed
  3. Ann Pharmacother. 2012 Feb;46(2):276-81 - PubMed
  4. Ann Pharmacother. 2014 Apr 28;48(7):863-869 - PubMed
  5. Acta Oncol. 2015 Jul;54(7):1001-7 - PubMed
  6. Support Care Cancer. 2016 Apr;24(4):1789-93 - PubMed
  7. Scand J Clin Lab Invest. 2017 Jul;77(4):237-246 - PubMed
  8. Cancer Res. 1973 Jun;33(6):1310-5 - PubMed

Publication Types